0000000000881847

AUTHOR

U. Keilholz

showing 3 related works from this author

Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC

2019

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (N = 496) and a validation set (DKTK MASTER cohort, N = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately re-analyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-nega…

APOBECmedicine.medical_treatmentImmunotherapyBiologymedicine.diseaseHead and neck squamous-cell carcinomaPhenotypeImmune checkpointstomatognathic diseasesImmune systemGene expressionCancer researchmedicineTechnology PlatformsExome
researchProduct

Intermittent Low-Dose IFN Gamma Treatment for Metastatic Renal Cell Carcinoma: Analysis of Factors Predicting Clinical Response and Long-Term Survival

1995

Background: Objective tumor remissions are induced by a variety of immunomodulating agents in a minority of patients suffering from metastasizing renal cell carcinoma. The results of different clinical studies, however, varied greatly for each of these treatment modalities. In order to elucidate potential causes for this variability and to further study the long-term results of intermittent low-dose IFN gamma therapy in patients with advanced renal cell cancer (RCC) we retrospectively analyzed factors predicting clinical response and long-term survival of 121 patients. Material and Methods: We retrospectively analyzed the clinical results of 5 phase II studies treating 121 patients with int…

Response rate (survey)OncologyCancer Researchmedicine.medical_specialtybusiness.industryLow doseWidespread DiseaseHematologyDiseasemedicine.diseaseOncologyRenal cell carcinomaInternal medicineLong term survivalImmunologymedicineLymphbusinessIfn gammaOncology Research and Treatment
researchProduct

Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC

2020

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (n = 496) and a validation set (DKTK MASTER cohort, n = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately reanalyzed. APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. This association was restricted to HPV-negative HNSCC samples. An APOBEC-enriched, HPV-negat…

MaleAPOBECCancer ResearchT-Lymphocytesmedicine.medical_treatment610BiologyCohort Studies03 medical and health sciences0302 clinical medicineGene expressionBiomarkers TumormedicineHumansExomeAPOBEC Deaminasestumor inflammationPapillomaviridaeExomeGeneImmune EvasionInflammationSequence Analysis RNASquamous Cell Carcinoma of Head and NeckPapillomavirus InfectionsAPOBECmutational signatureImmunotherapyMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaPhenotypeImmune checkpointddc:Gene Expression Regulation Neoplasticstomatognathic diseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisMutationCancer researchimmune checkpoint inhibitionFemalehead and neck cancerTranscriptome600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitInternational Journal of Cancer
researchProduct